- Home
- CTRM vs PULM Comparison
CTRM vs PULM Comparison
Compare CTRM & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTRM
- PULM
- Stock Information
- Founded
- CTRM 2016
- PULM 2003
- Country
- CTRM Cyprus
- PULM United States
- Employees
- CTRM N/A
- PULM N/A
- Industry
- CTRM Marine Transportation
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- CTRM Consumer Discretionary
- PULM Health Care
- Exchange
- CTRM Nasdaq
- PULM Nasdaq
- Market Cap
- CTRM 21.2M
- PULM 18.3M
- IPO Year
- CTRM N/A
- PULM N/A
- Fundamental
- Price
- CTRM $2.11
- PULM $4.73
- Analyst Decision
- CTRM
- PULM
- Analyst Count
- CTRM 0
- PULM 0
- Target Price
- CTRM N/A
- PULM N/A
- AVG Volume (30 Days)
- CTRM 39.8K
- PULM 15.8K
- Earning Date
- CTRM 11-06-2025
- PULM 11-07-2025
- Dividend Yield
- CTRM N/A
- PULM N/A
- EPS Growth
- CTRM N/A
- PULM N/A
- EPS
- CTRM N/A
- PULM N/A
- Revenue
- CTRM $67,859,415.00
- PULM $369,000.00
- Revenue This Year
- CTRM N/A
- PULM N/A
- Revenue Next Year
- CTRM N/A
- PULM $134.88
- P/E Ratio
- CTRM N/A
- PULM N/A
- Revenue Growth
- CTRM N/A
- PULM N/A
- 52 Week Low
- CTRM $1.91
- PULM $1.96
- 52 Week High
- CTRM $4.19
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- CTRM 48.73
- PULM 44.57
- Support Level
- CTRM $2.11
- PULM $4.83
- Resistance Level
- CTRM $2.22
- PULM $5.50
- Average True Range (ATR)
- CTRM 0.06
- PULM 0.26
- MACD
- CTRM 0.00
- PULM 0.03
- Stochastic Oscillator
- CTRM 33.71
- PULM 32.06
About CTRM Castor Maritime Inc.
Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under three reportable segments namely (i) the dry bulk segment (ii) the containership segment and (iii) the asset management segment. It generates maximum revenue from the Dry bulk segment.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).